Literature DB >> 24399338

Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision.

Peter S Hendricks1, C Brendan Clark, Matthew W Johnson, Kevin R Fontaine, Karen L Cropsey.   

Abstract

Hallucinogen-based interventions may benefit substance use populations, but contemporary data informing the impact of hallucinogens on addictive behavior are scarce. Given that many individuals in the criminal justice system engage in problematic patterns of substance use, hallucinogen treatments also may benefit criminal justice populations. However, the relationship between hallucinogen use and criminal recidivism is unknown. In this longitudinal study, we examined the relationship between naturalistic hallucinogen use and recidivism among individuals under community corrections supervision with a history of substance involvement (n=25,622). We found that hallucinogen use predicted a reduced likelihood of supervision failure (e.g. noncompliance with legal requirements including alcohol and other drug use) while controlling for an array of potential confounding factors (odds ratio (OR)=0.60 (0.46, 0.79)). Our results suggest that hallucinogens may promote alcohol and other drug abstinence and prosocial behavior in a population with high rates of recidivism.

Entities:  

Keywords:  Hallucinogen; criminal justice; lysergic acid diethylamide; positive psychology; psilocybin; psychedelic; recidivism

Mesh:

Substances:

Year:  2014        PMID: 24399338     DOI: 10.1177/0269881113513851

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  18 in total

Review 1.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

Review 2.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 3.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

Review 4.  Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Authors:  Rafael G Dos Santos; José Carlos Bouso; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2017-02-23

5.  Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.

Authors:  Elena Argento; M Eugenia Socias; Kanna Hayashi; JinCheol Choi; Lindsay Mackay; Devon Christie; M-J Milloy; Kora DeBeck
Journal:  Int J Drug Policy       Date:  2021-11-07

6.  Drug Use Disorders and Violence: Associations With Individual Drug Categories.

Authors:  Shaoling Zhong; Rongqin Yu; Seena Fazel
Journal:  Epidemiol Rev       Date:  2020-01-31       Impact factor: 6.222

7.  The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women.

Authors:  Elena Argento; Melissa Braschel; Zach Walsh; M Eugenia Socias; Kate Shannon
Journal:  J Psychopharmacol       Date:  2018-09-26       Impact factor: 4.153

Review 8.  Legal highs: staying on top of the flood of novel psychoactive substances.

Authors:  David Baumeister; Luis M Tojo; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

Review 9.  Psychedelics.

Authors:  David E Nichols
Journal:  Pharmacol Rev       Date:  2016-04       Impact factor: 25.468

10.  Trends and correlates of substance use disorders among probationers and parolees in the United States 2002-2014.

Authors:  Noelle E Fearn; Michael G Vaughn; Erik J Nelson; Christopher P Salas-Wright; Matt DeLisi; Zhengmin Qian
Journal:  Drug Alcohol Depend       Date:  2016-08-05       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.